Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Prince Eladnani, Raja; Bologna, Luca; Manetti, Mirko; Melchiorre, Daniela; Rosa, Irene; Dewarrat, Natacha; Suardi, Silvia; Amini, Poorya; Fernández, José A; Burnier, Laurent; Quarroz, Claudia; Reina Caro, Maria Desiré; Matsumura, Yasuhiro; Kremer Hovinga, Johanna Anna; Griffin, John H; Simon, Hans-Uwe; Ibba-Manneschi, Lidia; Saller, François; Calzavarini, Sara and Angelillo, Anne (2018). Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood, 131(12), pp. 1360-1371. American Society of Hematology 10.1182/blood-2017-09-800326

[img] Text
Simon_Targeting anticoagulant protein.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (6MB) | Request a copy

Improved treatments are needed for hemophilia A and B, bleeding disorders affecting 400,000 people worldwide. We investigated whether targeting protein S could promote hemostasis in hemophilia by re-balancing coagulation. Protein S is an anticoagulant acting as cofactor for activated protein C and tissue factor pathway inhibitor (TFPI). This dual role makes PS a key regulator of thrombin generation. Here, we report that targeting protein S rebalances coagulation in hemophilia. Protein S gene targeting in hemophilic mice protected them against bleeding, especially when intra-articular. Mechanistically, these mice displayed increased thrombin generation, resistance to activated protein C and TFPI, and improved fibrin network. Blocking protein S in plasma of hemophilia patients normalized in vitro thrombin generation. Both protein S and TFPIα were detected in hemophilic mice joints. Protein S and TFPI expression was stronger in joints of hemophilia A than hemophilia B patients when receiving on demand therapy, e.g., during a bleeding episode. In contrast, protein S and TFPI expression was decreased in hemophilia A patients receiving prophylaxis with coagulation factor concentrates, and comparable to osteoarthritis patients. These results establish protein S inhibition as both controller of coagulation and potential therapeutic target in hemophilia. The murine protein S silencing RNA approach that we successfully used in hemophilic mice might constitute a new therapeutic concept for hemophilic patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)

UniBE Contributor:

Prince Eladnani, Raja; Bologna, Luca; Dewarrat, Natacha; Amini, Poorya; Quarroz, Claudia; Reina Caro, Maria Desiré; Kremer Hovinga, Johanna Anna; Simon, Hans-Uwe and Angelillo, Anne

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0006-4971

Publisher:

American Society of Hematology

Language:

English

Submitter:

Jana Berger

Date Deposited:

21 Mar 2018 10:04

Last Modified:

18 Jan 2019 14:27

Publisher DOI:

10.1182/blood-2017-09-800326

PubMed ID:

29317453

BORIS DOI:

10.7892/boris.111471

URI:

https://boris.unibe.ch/id/eprint/111471

Actions (login required)

Edit item Edit item
Provide Feedback